Aniara Diagnostica

Jonas Kingo 

Executive V.P Co-Founder of Aniara Diagnostica, a division of Aniara Corporation founded by Ola Andersson

• Competence: Immunologist, Biochemist, Doctor in Medical Sciences
• Training: Biochemestry at the Lyon University-INSA (France), Immonology at the Medical School of Creteil (France), and PhD in Medical Sciences at Paris VII University
• More than 20 years of experience in developing advanced assay methods for hemostasis and thrombosis; in designing new techniques for the measurement of coagulation factors and blood activation markers applied to the early diagnosis of cardiovascular alterations and thrombotic tendencies; research and development of assays for auto-immune diseases associated with an increased risk of thrombosis; direction of clinical and epidemiological studies; management of a research and technical group of 36 scientists; coordination of international collaborative studies; major involvement in scientific communication (presentations at congress and publications).
• Original experience at the interface of fundamental research, technologies and clinical applications, with an expertise in thrombosis (causes and consequences) and its interactions.
• Major accomplishments: Discovery of PF4 as the target antigen in presence of heparin, for Heparin Induced Anitbodies, type II, and description of immune pathological mechanisms; creation of HYPHEN BioMed in 1999, with Anne-Marie Vissac.
• Personal: Born in 1952 in Barcelona, Spain; French citizen; married with two sons.

Ann Marie Vissac

Technical Director, HYPHEN BioMed

• Competence: Coagulation and immunological technology; laboratory technical management; Biological Chemistry Engineer.
• Training: Clinical Chemistry MT (ENC Paris, France); Biological Chemistry Engineer (SNIPF).
• Experience: Microbiology teacher (ENC, Paris, 1976); Biological Analysis Laboratory (Drs. Samama and Kerboul, Paris, 1977 to 1986); project leader in Research and Development of Immunological methods (Serbio, Stago group, Gennevilliers, 1986 to 1998); Technical Director of HYPHEN Biomed (Neuville-Sur-Oise, from 1998); Presentations at International congresses, and author or co-author of various papers.
• Practical experience in clinical applications of laboratory testing; development and validation of new assay methods, and especially immunoassays; epidemiological studies; clinical validation protocols. Complete experience in the field of laboratory techniques applied to the exploration of thrombosis, hemostasis and auto-immunity.
• Major accomplishments: participation to the discovery of PF4 as the target antigen for Heparin Induced Antibodies in Jean Amiral's research group; creation of HYPHEN BioMed with Jean Amiral in 1999.
• Personal: Born in Bastia (20 - France), in 1956; French citizen; married with a son and daughter.